Joseph Muenzer1, Christian J Hendriksz2, Zheng Fan3, Suresh Vijayaraghavan2, Victor Perry4, Saikat Santra2, Guirish A Solanki5, Mary Ann Mascelli6, Luying Pan6, Nan Wang6, Kenneth Sciarappa6, Ann J Barbier6. 1. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. Department of Clinical Inherited Metabolic Disorders, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK. 3. Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 4. Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 5. Department of Paediatric Neurosurgery, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK. 6. Shire, Lexington, Massachusetts, USA.
Abstract
PURPOSE: Approximately two-thirds of patients with the lysosomal storage disease mucopolysaccharidosis II have progressive cognitive impairment. Intravenous (i.v.) enzyme replacement therapy does not affect cognitive impairment because recombinant iduronate-2-sulfatase (idursulfase) does not penetrate the blood-brain barrier at therapeutic concentrations. We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery device (IDDD). A secondary endpoint was change in concentration of glycosaminoglycans in cerebrospinal fluid. METHODS: Sixteen cognitively impaired males with mucopolysaccharidosis II who were previously treated with weekly i.v. idursulfase 0.5 mg/kg for ≥6 months were enrolled. Patients were randomized to no treatment or 10-mg, 30-mg, or 1-mg idursulfase-IT monthly for 6 months (four patients per group) while continuing i.v. idursulfase weekly. RESULTS: No serious adverse events related to idursulfase-IT were observed. Surgical revision/removal of the IDDD was required in 6 of 12 patients. Twelve total doses were administrated by lumbar puncture. Mean cerebrospinal fluid glycosaminoglycan concentration was reduced by approximately 90% in the 10-mg and 30-mg groups and approximately 80% in the 1-mg group after 6 months. CONCLUSIONS: These preliminary data support further development of investigational idursulfase-IT in MPS II patients with the severe phenotype who have progressed only to a mild-to-moderate level of cognitive impairment.Genet Med 18 1, 73-81.
PURPOSE: Approximately two-thirds of patients with the lysosomal storage disease mucopolysaccharidosis II have progressive cognitive impairment. Intravenous (i.v.) enzyme replacement therapy does not affect cognitive impairment because recombinant iduronate-2-sulfatase (idursulfase) does not penetrate the blood-brain barrier at therapeutic concentrations. We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery device (IDDD). A secondary endpoint was change in concentration of glycosaminoglycans in cerebrospinal fluid. METHODS: Sixteen cognitively impaired males with mucopolysaccharidosis II who were previously treated with weekly i.v. idursulfase 0.5 mg/kg for ≥6 months were enrolled. Patients were randomized to no treatment or 10-mg, 30-mg, or 1-mg idursulfase-IT monthly for 6 months (four patients per group) while continuing i.v. idursulfase weekly. RESULTS: No serious adverse events related to idursulfase-IT were observed. Surgical revision/removal of the IDDD was required in 6 of 12 patients. Twelve total doses were administrated by lumbar puncture. Mean cerebrospinal fluid glycosaminoglycan concentration was reduced by approximately 90% in the 10-mg and 30-mg groups and approximately 80% in the 1-mg group after 6 months. CONCLUSIONS: These preliminary data support further development of investigational idursulfase-IT in MPS II patients with the severe phenotype who have progressed only to a mild-to-moderate level of cognitive impairment.Genet Med 18 1, 73-81.
Authors: Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith Journal: Pediatrics Date: 2009-11-09 Impact factor: 7.124
Authors: Joseph Muenzer; James E Wraith; Michael Beck; Roberto Giugliani; Paul Harmatz; Christine M Eng; Ashok Vellodi; Rick Martin; Uma Ramaswami; Muge Gucsavas-Calikoglu; Suresh Vijayaraghavan; Susanne Wendt; Suzanne Wendt; Ana Cristina Puga; Antonio Puga; Brian Ulbrich; Marwan Shinawi; Maureen Cleary; Diane Piper; Anne Marie Conway; Ann Marie Conway; Alan Kimura Journal: Genet Med Date: 2006-08 Impact factor: 8.822
Authors: Pericles Calias; Mikhail Papisov; Jing Pan; Nancy Savioli; Vasily Belov; Yan Huang; Jason Lotterhand; Mary Alessandrini; Nan Liu; Alan J Fischman; Jan L Powell; Michael W Heartlein Journal: PLoS One Date: 2012-01-18 Impact factor: 3.240
Authors: José Francisco da Silva Franco; Regina El Dib; Arnav Agarwal; Diogo Soares; Noala Vicensoto Moreira Milhan; Lilian Maria José Albano; Chong Ae Kim Journal: Intractable Rare Dis Res Date: 2017-08
Authors: Patricia I Dickson; Ilkka Kaitila; Paul Harmatz; Anton Mlikotic; Agnes H Chen; Alla Victoroff; Merry B Passage; Jacqueline Madden; Steven Q Le; David E Naylor Journal: Mol Genet Metab Date: 2015-07-26 Impact factor: 4.797